French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update

8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: In recent years, knowledge about cancer associated thrombosis has evolved considerably. Methods: Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of different scientific societies practicing in various settings. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS). Results: After a literature review, guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease and management from the data of available clinical trials and observational studies : epidemiology, initial treatment, treatment duration, extended treatment, recurrent thrombosis, central venous catheter thrombosis, incidental thrombosis, treatment in case of thrombocytopenia. Conclusion: These evidence-based guidelines are intended to guide the practical management of patients with cancer associated thrombosis

Author supplied keywords

Cite

CITATION STYLE

APA

Mahé, I., Meyer, G., Girard, P., Bertoletti, L., Laporte, S., Couturaud, F., … Sanchez, O. (2023). French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update. Respiratory Medicine and Research, 84. https://doi.org/10.1016/j.resmer.2023.101056

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free